COMP <GO>
VRTX vs MRK // FREE CASH FLOW YIELD
Vertex Pharmaceuticals Incorporated (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: VRTX 8
— MRK 7
▲ FREE CASH FLOW YIELD LEADER: MRK
LAST: $558.88 (+3.50%) • MKT CAP: $136.87B
fcf-yield
2.33%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
fcf-yield
3.42%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRTX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VRTX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.20% | 74.80% | +11.40 | VRTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.00% | 20.70% | -0.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 29.6x | 15.3x | +14.30 | MRK | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 2.33% | 3.42% | -1.09 | MRK | /fcf-yield <GO> |
| Operating Margin | 34.80% | 34.30% | +0.50 | VRTX | /operating-margins <GO> |
| Net Profit Margin | 32.90% | 28.10% | +4.80 | VRTX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.90% | 1.30% | +7.60 | VRTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.86 | 5.19 | +8.67 | VRTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | VRTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.60% | +0.40 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.7 | 56.9 | +10.79 | VRTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 0.92 | +0.10 | VRTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.2x | 18.4x | +13.80 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $136.87B | $361.02B | -$224.15B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VRTX REV | MRK REV | VRTX GROSS % | MRK GROSS % | VRTX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.00B | $65.01B | 86.2% | 74.8% | $3.19B | $12.36B |
| FY 2024 | $11.02B | $64.17B | 86.1% | 76.3% | -$790.3M | $18.10B |
| FY 2023 | $9.87B | $60.12B | 44.0% | 44.0% | $3.09B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRTX // BETA 1.02
MRK // BETA 0.92